. Author manuscript; available in PMC: 2016 Mar 15.

Published in final edited form as: Clin Cancer Res. 2015 Mar 16;21(18):4174–4183. doi: 10.1158/1078-0432.CCR-14-2759

Table 3. Multivariate survival analysis of recurrently mutated genes.

Variable	TTFT
Variable	HR	95% CI	P-Value
Hb<12g/dl	2.28	1.32-3.96	0.003
IGHV 100% identity	2.19	1.05-4.55	0.036
*NOTCH2*	2.12	1.02-4.40	0.044
	EFS
	HR	95% CI	P-Value
Plts<100×10⁹L	3.75	1.68-8.41	0.001
Lymphocytes <4×10⁹L	0.41	0.17-0.96	0.04
Age at diagnosis <65yrs	0.45	0.21-0.96	0.038
	OS
	HR	95% CI	P-Value
Hb<12gdl	2.18	1.12-4.23	0.02
Lymphocytes <4×10⁹L	2.35	1.11-4.97	0.03
Age at diagnosis <65yrs	0.09	0.03-0.27	<0.001
*TP53*	2.36	1.08-5.20	0.03

Footnote: TTFT Multivariate: 83 cases with 56 events; 92 cases with missing data. EFS Multivariate: 82 cases with 35 events; 93 cases with missing data. OS Multivariate: 134 cases with 38 events; 38 cases with missing data. Backwards-step regression was employed, including the following clinical variables (Hb<12gdl, Plts<100×10⁹L, Lymphocytes <4×10⁹L, Age at diagnosis <65yrs) and the representative gene status variables significantly associated with treatment, event and survival outcome in univariate analysis (Table 2). The TTFT model also included IGHV 100% identity, KLF2 and NOTCH2 mutation status. EFS and OS also included TP53 mutation status. Variables removed from the backwards-step regression are not shown.